Journal
NEUROSCIENCE LETTERS
Volume 648, Issue -, Pages 41-46Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2017.03.047
Keywords
Multiple sclerosis; Lysolecithin; IGF-1; Insulin; Remyelination; Rat; Intrathecal
Categories
Funding
- Swiss MS Society
- Hartmann-Muller Foundation, Zurich
- Desiree-and-Niels-Yde Foundation
- Swiss National Science Foundation [323530_151488]
- Senior Research Career Scientist award of the Dept. of Veterans Affairs
- Swiss National Science Foundation (SNF) [323530_151488] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
One main pathological hallmark of multiple sclerosis (MS) is demyelination. Novel therapies which enhance myelin repair are urgently needed. Insulin and insulin-like growth factor 1 (IGF-1) have strong functional relationships. Here, we addressed the potential capacity of IGF-1 and insulin to enhance remyelination in an animal demyelination model in vivo. We found that chronic intrathecal infusion of IGF-1 enhanced remyelination after lysolecithin-induced demyelination in the spinal cord of young and aged rats. Aged rats showed a weaker innate remyelination capacity and are therefore a good model for progressive MS which is defined by chronic demyelination. In contrast to IGF-1, Insulin had no effect on remyelination in either age group. Our findings highlight the potential use of IGF-1 as remyelinating therapy for MS, particularly the progressive stage in which chronic demyelination is the hallmark. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available